These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 8211493)

  • 1. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
    van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
    S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of gonadotrophin-releasing hormone analogues in gynaecology.
    Lo KW; Lau TK
    Chin Med J (Engl); 1997 Oct; 110(10):746-9. PubMed ID: 9642302
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of GnGH (GnRH-A) in gynecology].
    Ciardo A; Spina V; Aleandri V
    Minerva Ginecol; 1998; 50(1-2):25-9. PubMed ID: 9577152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gonadotropin-releasing hormone analogs].
    Krysiak R; Okopień B; Herman ZS
    Pol Merkur Lekarski; 2005 May; 18(107):585-9. PubMed ID: 16161962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral CA 125 levels in patients with uterine fibroids.
    Bischof P; Galfetti MA; Seydoux J; von Hospenthal JU; Campana A
    Hum Reprod; 1992 Jan; 7(1):35-8. PubMed ID: 1532397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of gonadotropin-releasing hormone agonists on adrenocorticotropin and cortisol secretion in adult premenopausal women.
    Wilson EE; Little BB; Byrd W; McGee E; Carr BR
    J Clin Endocrinol Metab; 1993 Jan; 76(1):162-4. PubMed ID: 8380603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
    Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
    Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CA-125 levels in the diagnosis and management of endometriosis.
    Lanzone A; Marana R; Muscatello R; Fulghesu AM; Dell'Acqua S; Caruso A; Mancuso S
    J Reprod Med; 1991 Aug; 36(8):603-7. PubMed ID: 1834843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GnRH agonists in the treatment of uterine leiomyomas.
    Bianchi S; Fedele L
    Acta Eur Fertil; 1989; 20(1):5-10. PubMed ID: 2675524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring therapy with a gonadotropin-releasing hormone analog: utility of MR imaging.
    Zawin M; McCarthy S; Scoutt L; Lange R; Lavy G; Vulte J; Comite F
    Radiology; 1990 May; 175(2):503-6. PubMed ID: 2109336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of GnRH agonists in gynaecology.
    Preutthipan S
    J Med Assoc Thai; 1993 Jan; 76 Suppl 1():11-8. PubMed ID: 8113648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
    Zeng C; Gu M; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GnRH-analogs in the therapy of uterine myomatosis].
    Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
    Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention.
    Schindler AE
    Gynecol Endocrinol; 2009 Dec; 25(12):765-7. PubMed ID: 19905992
    [No Abstract]   [Full Text] [Related]  

  • 17. Will GnRH antagonists assist in the treatment of benign gynaecological diseases?
    Felberbaum RE; Küpker W; Diedrich K
    Reprod Biomed Online; 2002; 5 Suppl 1():68-72. PubMed ID: 12537785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotrophin releasing hormone agonist (buserelin) in the treatment of endometriosis: changes in the extent of the disease and in CA 125 serum levels after 6-month therapy.
    Marana R; Muzii L; Muscatello P; Lanzone A; Caruso A; Dell'Acqua S; Mancuso S
    Br J Obstet Gynaecol; 1990 Nov; 97(11):1016-9. PubMed ID: 2147564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
    Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
    Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.
    Rein MS; Friedman AJ; Pandian MR; Heffner LJ
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):388-94. PubMed ID: 2116610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.